Lantus

Lantus is a long‑acting form of insulin glargine, a recombinant analogue of human insulin developed to help manage blood sugar levels in people living with diabetes mellitus, including both type 1 and type 2 forms. It provides a basal level of insulin activity that begins within a couple of hours after administration and continues steadily throughout the day, helping maintain more consistent blood sugar control.
The insulin glargine molecule is formulated so that after it is introduced under the skin, it forms microcrystals in the tissue. These microprecipitates slowly dissolve, releasing small amounts of active insulin over about 24 hours. This peak‑free action helps stabilise blood sugar levels between meals and overnight, which can be especially valuable in long‑term metabolic management.
By mimicking the body’s natural basal insulin release, Lantus supports glucose uptake into muscle and fat cells, and decreases sugar production by the liver, helping achieve balanced glucose levels throughout the day.
Common responses associated with insulin glargine include episodes of low blood sugar, localized reactions at the injection site such as redness or swelling, weight changes, and skin changes like thickening or indentations where the injection is given. Peripheral fluid retention and mild swelling can also occur in some cases.
Rare responses may include allergic reactions or shifts in potassium levels. Regular monitoring of glucose trends, general health, and lifestyle adjustments like balanced nutrition and consistent physical activity complement the effects of Lantus.
Used as part of a comprehensive support plan, Lantus’s long‑acting action offers stable baseline coverage that helps reduce fluctuations in glucose levels and contributes to overall metabolic balance in people managing diabetes.